Development of a Vaginal Extracellular Matrix Hydrogel for Combating Genitourinary Syndrome of Menopause
Advanced Materials · 2025
DOI: 10.1002/adma.202419977 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2025. Verfasst von Emma I Zelus und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shu Chien-Gene Lay Department of Bioengineering, UC San Diego, La Jolla, USA. Hauptthemen laut MEDLINE: Vagina, Hydrogels, Extracellular Matrix, Menopause. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NICHD NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Abstract (Originalsprache)
Genitourinary syndrome of menopause (GSM) is initiated by the hypoestrogenic state consequent to cessation of ovarian function and involves changes in all vaginal layers. These alterations include decreased epithelial proliferation and differentiation, impaired extracellular matrix (ECM) maintenance, pro‐inflammatory immune milieu, and smooth muscle atrophy. Patient satisfaction with existing treatments for GSM is low, due in part to their lack of therapeutic effect throughout all vaginal layers and reliance on hormonal treatments. Decellularized ECM therapeutics are known to facilitate soft tissue repair in a variety of applications. Thus, a porcine vaginal tissue‐derived decellularized ECM (vECM) hydrogel suitable for noninvasive topical intravaginal administration is developed specifically for vaginal repair. When applied in a rat model of surgical menopause, vECM significantly improves vaginal epithelial thickness and epithelial stem cell phenotype. Despite topical intravaginal application, vECM is also observed in the lamina propria and fibromuscularis, exerting a regenerative effect on the vaginal smooth muscle layer. Furthermore, vECM modulates macrophage density and promotes pro‐regenerative M2‐like phenotype within the vaginal tissue. Overall, the work herein demonstrates a new nonhormonal biomaterial treatment that counteracts pathological vaginal alterations – a hallmark of GSM – in an established preclinical model of menopause.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shu Chien-Gene Lay Department of Bioengineering, UC San Diego, La Jolla, USA.
- Sanford Consortium for Regenerative Medicine, La Jolla, USA.
- Sanford Stem Cell Institute, UC San Diego, La Jolla, USA.
- Department of Obstetrics, Gynecology and Reproductive Sciences, UC San Diego, La Jolla, USA.
- Department of Biochemistry and Molecular Genetics, Anschutz Medical Campus, University of Colorado, Boulder, USA.
ORCID-Profile: Karen L Christman
Förderung
- NIA NIH HHS
- NICHD NIH HHS
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Institute on Aging
Zitieren
APA
Zelus, E. I., Grime, J., Saviola, A., McCabe, M., Hansen, K. C., Alperin, M., & Christman, K. L. (2025). Development of a Vaginal Extracellular Matrix Hydrogel for Combating Genitourinary Syndrome of Menopause. Advanced Materials. https://doi.org/10.1002/adma.202419977
Vancouver
Zelus EI, Grime J, Saviola A, McCabe M, Hansen KC, Alperin M, et al. Development of a Vaginal Extracellular Matrix Hydrogel for Combating Genitourinary Syndrome of Menopause. Advanced Materials. 2025. doi:10.1002/adma.202419977
BibTeX
@article{Zelus2025,
author = {Zelus, Emma I and Grime, Jacqueline and Saviola, Anthony and McCabe, Maxwell and Hansen, Kirk C and Alperin, Marianna and Christman, Karen L},
title = {Development of a Vaginal Extracellular Matrix Hydrogel for Combating Genitourinary Syndrome of Menopause},
journal = {Advanced Materials},
year = {2025},
doi = {10.1002/adma.202419977}
}
EUVIMED